Home›Stock Screener›Auro Laboratories

Auro Laboratories Share Price Today | Stock Price & Auro Laboratories Share Screener

AUROLAB Pharmaceuticals & Biotechnology
Live Share Price BSE
₹247.60
▲ 5.90 (2.44%)
2026-11-20 00:00:00

As of November 20, 2026, the live Auro Laboratories share price (BSE: AUROLAB) is ₹247.60, up 2.44% from the previous close, with shares trading between ₹241.70 and ₹254.90 in today's trading session, and a 52-week range of ₹207.20–₹302.05. Track AUROLAB market cap trends to gauge the company's total market size. Use the Auro Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Auro Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹10 and net income of ₹1, with EBITDA of ₹3, an operating margin of 27.0% and a profit margin of 10.0%.

Auro Laboratories Market Cap ₹144.69 Cr.
AUROLAB P/E Ratio (TTM) 31.20
Auro Laboratories P/B Ratio 3.15
EPS (TTM) ₹5.67
Dividend Yield -
Debt to Equity 1.21
AUROLAB 52 Week High ₹302.05
Auro Laboratories 52 Week Low ₹207.20
Operating Margin 27.00%
Profit Margin 10.00%
AUROLAB Revenue (TTM) ₹10.00
EBITDA ₹3.00
Net Income ₹1.00
Total Assets ₹121.00
Total Equity ₹46.00

Auro Laboratories Share Price Chart

Track the current stock price of Auro Laboratories with an interactive chart. Analyse AUROLAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Auro Laboratories stock quote in one place.

The quote of ₹247.60 sits between the 52-week low of ₹207.20 and the 52-week high of ₹302.05, and the latest session moved 2.44% from the previous close.

Auro Laboratories Company Profile - Fundamental Screener

Screen Auro Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AUROLAB shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE292C01011.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE292C01011

Auro Laboratories Balance Sheet Screener

Screen AUROLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹121, up from ₹99 in 2025.

Latest statistics put total assets at ₹121 and shareholder funds at ₹46, with a leverage ratio of 1.21.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 121 99 86 56 55 42 32 34 30 27
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 75 21 22 13 14 14 14 15 13 13

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 46 35 20 4 3 4 5 10 11 11
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 46 43 42 34 32 29 22 17 13 9
Share Capital 6 6 6 6 6 6 6 6 6 6
Reserves & Surplus 40 37 36 28 25 22 15 11 7 3

Auro Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Auro Laboratories income statement and profit fundamentals. Analyze AUROLAB quarterly results. Auro Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2025-Sept, revenue was ₹10 and net profit was ₹1, equal to earnings per unit of ₹1.15, at an operating margin of 27%.

In that period expenses were ₹7, interest cost ₹1 and tax ₹1. The next period listed, 2025-Jun, shows revenue of ₹3 and net profit of ₹0.

Item 2025-Sept 2025-Jun 2024-Sept 2024-Jun

Revenue and Expenses

Revenue 10 3 3 6
Expenses 7 3 2 4

Operating Costs and Margins

EBITDA 3 0 1 2
Operating Profit % 27.00% 1.00% 23.00% 23.00%
Depreciation 1 0 0 0
Interest 1 0 0 0

Profit and Earnings

Profit Before Tax 2 0 1 1
Tax 1 0 0 0
Net Profit 1 0 0 1
EPS 1.15 -0.17 0.57 1.21

Auro Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen AUROLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹2, and net cash flow was an inflow of ₹1.

Over the same period, investing activities used ₹15 and financing activities provided ₹14.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 2 5 19 3 -7 13 9 7 6 7
Investing Activities -15 -24 -39 -5 -5 -4 -2 -3 -3 -2

Financing and Net Cash

Financing Activities 14 18 19 -8 10 -1 -6 -2 -2 -4
Net Cash Flow 1 -1 -1 -10 -2 9 2 2 1 1

Auro Laboratories Shareholding Pattern Screener

See Auro Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Auro Laboratories promoter holding and ownership changes for AUROLAB on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 52.40%, foreign institutions 0.00%, domestic institutions 0.01% and the public 36.74%, spread across 8,280 shareholders.

The shareholder count was 8,280 in 2026-Sept, compared with 8,315 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 52.40% 52.40% 52.18% 52.18% 52.18% 52.18% 52.18% 52.15%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 36.74% 36.56% 36.28% 36.26% 36.35% 36.42% 36.57% 36.15%
Other Holding 10.85% 11.02% 11.54% 11.56% 11.47% 11.40% 11.25% 11.69%
Shareholder Count 8,280 8,315 8,405 8,640 8,860 8,916 9,102 9,265

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Auro Laboratories. Auro Laboratories dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Auro Laboratories.

Auro Laboratories Stock Index Membership - Nifty & Sensex

See which indices include Auro Laboratories stock. Check AUROLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Auro Laboratories is not part of any tracked indices.
Only major market indices are tracked in our system.

Auro Laboratories Market Events Screener - Corporate Actions

Get Auro Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Auro Laboratories stock events that may affect AUROLAB share price, along with derivatives, futures and options activity and sector gainers.

12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 13, 2026, with a record date of November 13, 2026.

It is followed by Quarterly Result Announcement dated August 14, 2026 and Annual General Meeting dated August 11, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-13 2026-11-13 Quarterly Result Announcement NA -0.11%
2026-08-14 2026-08-14 Quarterly Result Announcement NA 2.28%
2026-08-11 2026-08-11 Annual General Meeting NA -7.74%
2026-05-29 2026-05-29 Quarterly Result Announcement NA 0.89%
2026-02-05 2026-02-05 Quarterly Result Announcement NA 22.56%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -2.46%
2025-09-25 2025-09-25 Annual General Meeting NA -2.73%
2025-08-14 2025-08-14 Quarterly Result Announcement NA -3.89%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 0.06%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -2.41%
2024-11-11 2024-11-11 Quarterly Result Announcement NA -0.22%
2024-06-28 2024-06-28 Annual General Meeting NA -13.67%

Auro Laboratories Competitors Screener - Peer Stocks Comparison

Screen AUROLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 450,523 41.10 61,674 12.69% 11,565 63.60
Divis Laboratories 297,750 90.70 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 179,340 84.50 13,886 20.34% 2,138 47.27
Laurus Labs 125,304 98.10 6,868 22.01% 890 69.60
Zydus Life Science 119,710 27.60 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,653 41.70 35,059 3.90% 4,158 70.24
Cipla 112,615 39.40 29,045 2.24% 3,870 54.92
Mankind Pharma 108,986 48.40 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,702 26.40 34,145 5.56% 3,503 66.06
Lupin 90,763 17.30 29,039 26.75% 5,356 44.92

Auro Laboratories Company Announcements - News & Reports Screener

Screen AUROLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 21, 2026.

The next most recent announcements are dated November 21, 2026 and October 31, 2026.

Date Update Actions
2026-11-21 Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026. -
2026-11-21 Board Meeting Outcome for Dated November 13 2026. -
2026-10-31 Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended September 30 2026. -
2026-10-13 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-23 Closure of Trading Window -
2026-08-17 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-14 Un-Audited Financial Results For The Quarter Ended June 30 2026. -
2026-08-14 Board Meeting Outcome for Outcome Of Board Meeting Held On August 14 2026. -
2026-08-13 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-11 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-10 Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30 2026. -
2026-07-20 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-16 Regulation 36(1)(B) Of SEBI (LODR) Regulations 2015 -
2026-07-16 Reg. 34 (1) Annual Report. -
2026-07-16 Notice Of 37Th Annual General Meeting (AGM) Scheduled On Tuesday August 11 2026 -
2026-07-15 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-07-15 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-06-30 Announcement under Regulation 30 (LODR)-Change in Management -
2026-06-30 Board Meeting Outcome for Outcome Of The Board Meeting Dated June 30 2026 -
2026-06-26 Closure of Trading Window -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹247.60, within a 52-week range of ₹207.20 to ₹302.05. The P/E ratio is 31.20 and the P/B ratio is 3.15, with earnings per unit of ₹5.67. Market capitalisation stands at ₹144.69 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on November 23, 2026. This page covers 10 balance sheet periods, 4 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.